Oncologists were one of the few provider groups to register support for the FDA rule, reflecting the challenge of assessing rapidly expanding cancer test offerings.

The companies have partnered with the goal of streamlining point-of-care access to Guardant's genomic cancer test portfolio.

The UK government said that it plans this year to repeal regulations specific to COVID-19 tests as part of the alignment with EU Common Specifications.